Loading...

Pacific Blue™ anti-human HLA-DR Antibody

Pricing & Availability
Clone
L243 (See other available formats)
Regulatory Status
RUO
Other Names
Major Histocompatibility Class II, MHC class II
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
L243_Blue_022008
Human peripheral blood lymphocytes stained with L243 Pacific Blue™
  • L243_Blue_022008
    Human peripheral blood lymphocytes stained with L243 Pacific Blue™
See Pacific Blue™ spectral data
Cat # Size Price Quantity Check Availability Save
307623 25 µg 100€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
307624 100 µg 212€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
307633 100 tests 226€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
test size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
µg sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.
Concentration
µg sizes: 0.5 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The HLA-DR antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis.
For test size, the suggested use of this reagent for immunofluorescent staining is 5 µl per 106 cells in 100 µl volume.
For µg sizes, the suggested use of this reagent for immunofluorescent staining is ≤0.5 µg per 106 cells in 100 µl volume.
It is recommended that the reagent be titrated for optimal performance for each application.

* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Violet Laser (405 nm)
Application Notes

The L243 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. Clone L243 binds a conformational epitope on HLA-DRa which depends on the correct folding of the aß heterodimer.19

Additional reported applications (for the relevant formats) include: immunoprecipitation8, Western blotting8, in vitro blocking of mixed lymphocyte reactions9,10, depeletion of MHC class II cells7, immunohistochemical staining of acetone-fixed frozen sections4,5, and spatial biology (IBEX)21,22. For sensitive functional assays, we recommend using the Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 307648, 307665 - 307669).

Application References
  1. Brodsky F. 1984. Immunogenetics 19:179.
  2. Robbins P, et al. 1987. Human Immunol. 18:301.
  3. Stites D, et al. 1986. Clin. Immunol. Immunopathol. 38:161.
  4. Warnke R, et al. 1980. J. Histochem. Cytochem. 28:771. (IHC)
  5. Engleman E, et al. 1981. P. Natl. Acad. Sci. USA 78:1791. (IHC)
  6. Zipf T, et al. 1981. Cancer Res. 41:4786.
  7. Goodier M, et al. 2000. J. Immunol. 165:139. (Depletion)
  8. Esser M, et al. 2001. J. Virol. 75:6173. (IP, WB)
  9. Kalka-Moll WM, et al. 2002. J. Immunol. 169:6149. (Block)
  10. Wang RF, et al. 1999. Science 284:1351. (Block)
  11. Zaba LC, et al. 2007. J. Exp. Med. 204:3183. PubMed
  12. Fujita H, et al. 2009. P. Natl. Acad. Sci. USA 106:21795. PubMed
  13. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  14. Goncalves RM, et al. 2010. Infect. Immun. 78:4763. PubMed
  15. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  16. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
  17. Stein R, et al. 2011. Leuk. Lymphoma 52:273.
  18. Galkowska H, et al. 1996. Vet. Immunol. Immunopathol. 53:329.
  19. Moro M, et al. 2005. BMC Immunol. 6:24.
  20. Lauterbach N, et al. 2014. Mol Immunol. 59:19. PubMed
  21. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  22. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Fujisaka Y, et al. 2018. Oncol Lett. 15:509. PubMed
  2. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  3. Antonova LV, et al. 2019. Polymers (Basel). 11:1. PubMed
  4. Dulau–Florea AE, et al. 2018. Am J Clin Pathol. 150:273. PubMed
  5. Mello FV, et al. 2019. Cell Death Discov. 0.25625. PubMed
  6. Kuai J, et al. 2009. Rheumatology. 48:1352. PubMed
  7. Vries R, et al. 2012. PLoS One. 8:e1002885. PubMed
  8. Mesman A, et al. 2012. PLoS One. 7:e49573. PubMed
  9. Santos J, et al. 2013. J Transl Med. 11:18. PubMed
  10. Vries R, et al. 2014. J Virol. 88:4423. PubMed
  11. Blish C, et al. 2014. J Virol. 88:5894. PubMed
  12. Greer A, et al. 2014. PLoS One. 9:99084. PubMed
  13. Bennett T, et al. 2014. Clin Lymphoma Myeloma Leuk. 14:305. PubMed
  14. Quast I, et al. 2015. Neurol Neuroimmunol Neuroinflamm. 2: e148. PubMed
  15. Garcia-Montero A, et al. 2016. Blood. 127: 761 - 768. PubMed
  16. Huang SSY, et al. 2021. Biology. 10(8):. PubMed
  17. Elgamal S, et al. 2021. JCI Insight. 6:. PubMed
  18. Smith A, et al. 2021. Tissue Eng Part C Methods. 27:49. PubMed
  19. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  20. Mirchandani AS, et al. 2022. Nat Immunol. 23:927. PubMed
  21. Hu Z, et al. 2022. Nat Metab. 4:759. PubMed
  22. Aru B, et al. 2023. Balkan Med J. 40:117. PubMed
RRID
AB_493664 (BioLegend Cat. No. 307623)
AB_493665 (BioLegend Cat. No. 307624)
AB_1595444 (BioLegend Cat. No. 307633)

Antigen Details

Structure
Ig superfamily, MHC class II, heterodimeric transmembrane protein, 36 kD heavy and 27 kD light chain
Distribution

B cells, activated T cells, monocytes/macrophages, dendritic cells, other APCs

Function
Peptide presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, Macrophages, Monocytes, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Levacher M, et al. 1990. Clin. Exp. Immunol. 81:177.
2. Terstappen L, et al. 1990. J. Leukocyte Biol. 48:138.
3. Edwards JA, et al. 1986. J. Immunol. 137:490.
4. van Es A, et al. 1984. Transplantation 37:65.
5. O'Doherty U, et al. 1994. Immunology 82:487.
6. Thomas R, et al. 1994. J. Immunol. 153:4016.
7. Grouard G, et al. 1996. Nature 384:364.

Gene ID
3122 View all products for this Gene ID 3123 View all products for this Gene ID
UniProt
View information about HLA-DR on UniProt.org
Go To Top Version: 2    Revision Date: 06/17/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account